

WORKSHOP

San Francisco Bay Area Workshop: Antibody Drug Conjugates (ADC) Based Anticancer Therapeutics: Discovery, Development and Regulatory Challenges

Date/Time: 8:45 AM – 5:30 PM, March 23, 2015

Venue: Crowne Plaza Hotel, Foster City, CA

Speakers: Bogdan Olenyuk (*University of Southern California*), Tom Pillow (*Genentech*)

Samadhi Vitharana (*Takeda*), Christine O'Day (*Seattle Genetics*), Kedan Lin (*Genentech*)

Jagath Junutula (*Cellerant Therapeutics*)

Organizers: Tom Pillow (*Genentech, Inc.*), Robyn Rourick (*Genentech, Inc.*)

Fees: Regular - \$195; Students & Unemployed - \$35; Vendor Show: \$475

Registration: www.PBSS.org

Workshop Outline:

With several regulatory approvals, antibody drug conjugates (ADC) have become an important class of anticancer therapeutics. ADCs are complex biotherapeutics combining the specific targeting properties of large molecules and the cytotoxicity of small molecule drugs. Due to their complexity, the interdependence of diverse analytical methodologies and clinical pharmacology is crucial to understanding safety and efficacy relationships. There is a need for sharing ADC analytical and clinical pharmacology information for mutual learning amongst scientists of different disciplines.

- Antibody-drug conjugates as anticancer therapeutics: biological and therapeutic principles and strategies
- ADC conjugation chemistries and heterogeneity
- Analytical characterization and formulation development of ADCs
- Bioanalytical and LC-MS/MS assays for ADCs: multi-disciplinary, large / small molecule approaches and clinical strategies
- ADC Biotransformation, clinical pharmacology and clinical development
- Regulatory submissions and meeting post-approval commitments